about
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressorProinvasion metastasis drivers in early-stage melanoma are oncogenes.Feedback circuit among INK4 tumor suppressors constrains human glioblastoma developmentGOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancerHigh-resolution genomic profiles of human lung cancerPassenger deletions generate therapeutic vulnerabilities in cancerA landscape of driver mutations in melanomaMelanoma genome sequencing reveals frequent PREX2 mutationsInternational network of cancer genome projects.PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomasThe genomic complexity of primary human prostate cancerA comprehensive catalogue of somatic mutations from a human cancer genomeFoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasisBcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastomaEmerging patterns of somatic mutations in cancerThe RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissuesThe somatic genomic landscape of chromophobe renal cell carcinomaA genetic screen for candidate tumor suppressors identifies RESTFoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisThe somatic genomic landscape of glioblastomaMutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in miceNozzle: a report generation toolkit for data analysis pipelines.HiCPlotter integrates genomic data with interaction matrices.Molecular characterization of the tumor microenvironment in breast cancer.BRAF activation initiates but does not maintain invasive prostate adenocarcinomaIntegrative genome comparison of primary and metastatic melanomas.Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapyMutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Mycp53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.A role for ATF2 in regulating MITF and melanoma development.Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.Making sense of cancer genomic data.Mig-6 controls EGFR trafficking and suppresses gliomagenesisYap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancerPattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBMAn X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
P50
Q24299628-C53BB4BB-595C-4D2E-9003-FFCF6A48F2F6Q24312173-B2E8C65D-FF40-41A7-BE40-9D68D8D435A1Q24317761-3172B607-4160-4425-BC01-4A3A8D324E06Q24339293-4C4FD4C3-5988-4732-9B38-ECB1C6135AA4Q24530598-A58F423F-5F9D-461A-B953-ED156E283D80Q24598469-D445D9FC-498D-44FA-9D7D-CD1B2188F8F3Q24603357-AC71706E-2FA8-46FB-B10C-69368FCF00C0Q24610463-C56EC764-07E2-4F75-B54A-111C563A4A4CQ24611474-28646C28-FAD6-49EF-8F9A-19879DF56A36Q24615768-C5A81DB3-77D5-4075-B75E-60C7DA3B03EAQ24617949-103A640D-D503-458F-9BC3-AFD8442A2AEDQ24628532-D74F2A9C-3EE0-440D-9A58-6FADAAD96565Q24630630-4181909D-D975-4034-ACC7-9FBD4732E997Q24670606-3ACF6538-B3A4-413F-A554-BE3EC0CFABFEQ27014126-91B2391D-383D-4FBC-B347-5790B748C06BQ27853045-D184028A-2AB0-4E5F-94D9-13D2201D65CFQ27853175-230A1436-B467-4BA3-B248-EFD86CECDF18Q28217578-F16A20D4-CEA1-47AB-90AE-C5C43471FC5BQ28246658-CF1B25AC-DB03-48C0-82A3-36EFAA30E51AQ28257011-C34E45DB-5726-431F-8C4E-91D56FAFCA01Q28285131-B8738357-DCAB-47B0-9B74-90A745B63D06Q28300185-78993010-4FC2-4C0C-91D3-15C405456ECCQ28593469-1821B144-976B-4A5E-9351-C8BC921E728DQ30590421-9EA45CEA-B7C8-4E6E-B60B-4C3A187F9B71Q30995452-C434F443-B857-4162-8676-8D61959C2231Q31095898-588A25D1-B7D0-46B7-A2B6-2685BAD49638Q33392719-096B7092-C324-4287-96B6-9EE5BDBD0937Q33592837-0BC7B1D2-2CC1-453A-B595-1B98016C1B68Q33592837-CA125BD1-C030-4D0C-AAC8-596E10DCE943Q33598694-015365D8-1FF0-4035-A33B-ADD05A17AE63Q33598694-29FA53A7-EE05-45BB-AC86-12A97C967316Q33664297-D8176B9F-AF52-4ED5-93D5-3C3C26D95362Q33696336-F23FE691-5317-4808-A9E6-27203D3CA1B8Q33733341-67D8A22E-7D9A-4111-9B09-8DFDEDEEAE40Q33784589-A0ECD339-F059-40D0-87B4-08B556D5D5C2Q33788690-1ABED62B-453A-47A1-8903-5773F9192EE9Q33806005-68FB678F-E702-4886-86F6-CCBBA1334B75Q33846850-CEED1DB5-62F8-4358-BFD1-D42120C9E106Q33859568-F653D503-B5B0-475E-A1E8-8869E2ED68C1Q33943271-E8F7EF84-F7A9-4B91-B3E7-1259142E7894
P50
description
American dermatologist
@en
dermatoloog
@nl
dermatóloga estadounidense
@es
name
Lynda Chin
@ast
Lynda Chin
@de
Lynda Chin
@en
Lynda Chin
@es
Lynda Chin
@nl
Lynda Chin
@pt
type
label
Lynda Chin
@ast
Lynda Chin
@de
Lynda Chin
@en
Lynda Chin
@es
Lynda Chin
@nl
Lynda Chin
@pt
prefLabel
Lynda Chin
@ast
Lynda Chin
@de
Lynda Chin
@en
Lynda Chin
@es
Lynda Chin
@nl
Lynda Chin
@pt
P108
P106
P108
P21
P31
P569
1968-01-01T00:00:00Z